Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Michael Kelley, MD
Duke University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Duke University Medical Center
Durham, North Carolina, United States
- Durham Va Medical Center
Durham, North Carolina, United States
- Duke Raleigh
Raleigh, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2008
- Primary completion
- 30 Jun 2013
- Completion
- 30 Jun 2013
- Last update posted
- 30 Jun 2016
- Registered enrollment
- 37
- Registry id
- NCT00787267
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.